Washington Companies Refuses Safety Recommendations

LAS VEGAS, NV, Jul 10, 2020 – (ACN Newswire) – Through the discovery process in an ongoing federal lawsuit emails were provided of a safety meeting held at the Washington Companies Modern Machinery office in Rochester, WA following a tragic preventable bridge strike. The notes from the meeting show that its employees presented several safety improvement suggestions to the Washington Companies management. The internal meeting was to see if there were reasons to alter their site-specific safety procedures on what to do with outgoing equipment shipments after a bridge strike from equipment loaded incorrectly at the Washington Company site. There were several safety related ideas present which would have helped Washington Companies become a progressive shipper in the national campaign to stop accidental bridge strikes.

This Komatsu sub-contractor forwarded the safety meeting recommendation to a Mr. Jeremy Holt, Import Procurement Manager of the Komatsu America Supply Chain Division. Mr. Holt's response, on behalf of Komatsu, was "at this point I would not offer any directions to the carriers." Effectively, this response shuts down the Komatsu sub-contractors desire to do the right thing in protecting the United States interstate system from future bridges strikes, the motoring public from debris from future bridge strikes, and the American truckers transporting dangerous cargo unaware. There seems to be contempt by this international company to become engaged in the United States "Good Samaritan" philosophy of "Just do the Right Thing".

In the end, Komatsu and its sub-contractor Washington Companies Modern Machinery site was more concerned about becoming legally involved if the facility were to warn the driver and carrier of an observed unsafe condition before leaving their facility. The meeting participants failed to take into consideration Washington Companies contractual obligation to load Komatsu (KAC) equipment per the KAC loading configurations versus what a driver might want the site to do. The meeting notes show the procedures Modern Machinery finally re-adopted would load the load without concern for the safety of the motoring public, public infrastructure, and the truck driver.

It is the contention in the on-going Federal lawsuit that Washington Companies and Komatsu had no desire to become a steward of safe shipping, as shown by their lack of concern for the safety of the equipment they load once it leaves their Modern Machinery Rochester, WA site. This lack of safety culture was present when they loaded two Komatsu excavators over height causing the load to strike a major bridge along the I-5 interstate in Washington State.

Modern Machinery discussions confuses the duty between how a commercial truck driver wants the equipment placed on his trailer for weight distribution versus the shipper's duty to package the equipment for transport correctly, which is required by Komatsu the manufacturer to be configured for safe highway transportation.

Modern Machinery a part of a large consortium of privately held companies collectively known as the Washington Companies, owned by billionaire Dennis R. Washington. Modern Machinery sells and rents high quality heavy equipment and provides product support to the construction, mining, and forestry industries. The Modern Machinery terminal in Rochester, WA is a home to a large staging area for a variety of Komatsu product brought from overseas awaiting shipment to other Komatsu dealers.

ETON is a Las Vegas-based premier transportation company serving the Western United States with equipment, professional drivers and superior on-time service.

Komatsu America Corp. is a U.S. subsidiary of Komatsu Ltd., (OTCMKTS: KMTUY) the world's second largest manufacturer and supplier of earth-moving equipment, consisting of construction, mining and compact construction equipment.

Mitchell Truman, ETON.me
http://www.ETON.me, +(702) 348 6370
Environmental Transportation of Nevada, LLC

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Komnas HAM Papua presents the case of victim MB’s civilian death in Asiki

Jayapura, Papua, Indonesia, Jul 10, 2020 – (ACN Newswire) – The Papuan Representative Office of the National Commission on Human Rights of the Republic of Indonesia (Komnas HAM) revealed the case of a civilian death in Asiki, Boven Digoel Regency, the victim named Marius Betera, on May 16th 2020. This comes after completing a field investigation in order to meet the demand made by an NGO and the victim's family on Wednesday.

The coordinator of Komnas HAM Papua investigation team, Frits Ramandey, in his press statement in Jayapura, said that this investigation result must be disclosed to the people, the victim's family, and the NGO in order to find the cause of death of Marius Betera (40) last May 2020. Korindo was proven not to be involved in the death and did not violate human rights.

Frits said that the field investigation by Komnas HAM is done by visiting the location of incident in Asiki, Boven Digoel Regency and asking for information from the local residents, the Catholic church diocese, and the victim's wife.

The findings by the Papuan Representative Office of Komnas HAM RI are based on facts, data and information gathered from a number of witnesses and several related parties including an inspection on the location of the land that had been used by the victim, Marius Betera to plant bananas inside the oil palm plantation area owned by PT. TSE POP A Camp 19.

"Regarding the position or location of the banana trees at the plantation, the Papuan Representative Office of Komnas HAM RI received three different informations," said Frits accompanied by the Acting Head of Komnas HAM, Melchior S. Weruin, in his statement to the reporters.

Based on the information obtained from the field, the banana trees were owned by the victim, planted on land was legally owned by the palm oil company PT. TSE POP A.

As for the company's policy, according to Frits Ramandey, the Papuan Representative Office of Komnas HAM RI did find that inside the plantation area of PT. TSE POP A Camp 19, there are banana trees planted by residents on the roadside.

Frits expected the company to be firm in prohibiting if the land is used by other people for planting. According to Frits, if such condition is not immediately fixed, it will potentially create similar conflicts in the future.

Furthermore, based on the findings by Komnas HAM in the field, the victim Marius Betera's anger was caused by his unwillingness to let his banana trees be removed by a certain party.

Frits further explained that to protest, Marius Betera came to Police Post Camp 19 to report the removal of his banana trees but did not meet the Head of Police Post.

As a result of not being able to meet the Head of Police Post, according to Frits, the victim Marius Betera's anger was peaked when he experienced violent acts from a police officer with initials MY.

The Papuan Representative Office of Komnas HAM RI stated that from the information gathered from the perpetrator and witnesses in the field, the violence caused by the police officer MY against the victim Marius Betera can be categorized as an excessive, arbitrary, and unprofessional act.

The involvement of this police officer, according to Frits, has violated the National Police Chief Regulation No.1 and No.8 of 2009 on the Implementation of Human Rights Principles and Standards in Discharge of Duties of the Indonesian National Police article 11 letter g which states that police officers are prohibited from carrying out punishments and physical acts which are not based on law.

Moreover, from the doctor examination result at POP A Camp 19 clinic and other parties, as evidenced by the doctor's post-mortem result, according to Frits, the Papuan Representative Office of Komnas HAM considered that there was no medical evidence to confirm the death of victim Marius Betera was caused by violent acts by a police officer.

Komnas HAM has recommended to the Regional Police Chief of Papua that he carry out a law enforcement process against the police officer who allegedly committed violent acts toward the civilian Marius Betera at Camp 19 Asiki, Boven Digoel Regency on May 16th 2020..

Content & Media Relation Officer
Antara News Agency
Telephone: +62 857 7697 0137
Email: primasatya.antara@gmail.com

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

HK Main-Board Listed Tianda Pharmaceuticals(00455.HK) , A Promising Outlook for Growth

HONG KONG, Jul 10, 2020 – (ACN Newswire) – With the successive introduction of the "Opinions on Facilitating the Inheritance, Innovation and Development of Traditional Chinese Medicine (TCM)" in certain provinces in mainland China and the "Regulations on Traditional Chinese Medicine" proposed by the Beijing municipality (Drafted Regulations on TCM for Public Opinions), the TCM industry has embarked on a rapid development. The value of some Hong Kong listed small and mid-cap companies are gradually unveiled. Here is an example, Tianda Pharmaceuticals Limited (00455.HK), which emphasizes on "the development of the Chinese medicine industry as the foundation, the development of innovative medicines and medical technologies and the development of quality medical and health care services". The company has been drawing the attention from the market recently.

Headquartered in Hong Kong, the company has sales and distribution centers in Shenzhen, China and Sydney, Australia, which are responsible for sales network expansion and branding in Hong Kong, China, Australia, and global markets. At present, the company's products include chemical products, biological drugs, Chinese patent medicines, herbal medicines, herbal decoction pieces, health care products and supplements, covering the treatment of cardiovascular diseases, pediatric diseases, influenza and respiratory diseases, anti-infectives, detoxification, oncology and other therapeutic areas. In addition, the company has also developed a series of health care products and supplements under the brand names of "Herb Valley" and "Tuokang".

Opportunities are hidden in crisis
With the recent pandemic raging across the world, except for masks, alcohol and other basic epidemic prevention items, the demand for related medicines has also increased significantly. For example, the Ribavirin, one of the Tianda Pharmaceuticals's products, has been popular since the pandemic. In particular, at the early stage of the outbreak, Tianda Pharmaceuticals raced against time and quickly collaborated with leading Chinese medicine experts to develop a TCM formulas series to combat the disease, namely "Anti-Epidemic Formula 1" (for prevention), "Anti-Epidemic Formula 2" (for remedy) and "Anti-Epidemic Formula 3" (for rehabilitation) , and launched anti-epidemic campaigns in Guangdong, Hong Kong and Macau, to provide complimentary TCM consultation and Anti-Epidemic Formula 1 to more than 1,000 individuals, which was well received by society. In April 2020. Anti-Epidemic Formula 1 was approved for entry into the Australian Register of Therapeutic Goods as a listed medicine. It is the first TCM product to be registered in a market outside of China with preventive effects against influenza and the coronavirus disease, representing a a big step forward for Tianda Pharmaceuticals' TCM internationalization strategy .

TCM Industry has promising prospects as policies continue to be favorable
"It is expected that China's TCM and health industry may exceed 3 trillion yuan by 2020, and the average compound annual growth rate will remain at 20%." — Mentioned in the white paper entitled "TCM in China" published by State Council Information Office of the People's Republic of China. Moreover, it is expected the TCM market size may reach 170.8 billion yuan by 2022 and exceed 200 billion yuan by 2024, with an average annual compound growth rate of 10%. In 2020, the TCM market is expected to reach 580.6 billion yuan with a compound growth rate of 8.2%. With the growing awareness of using TCM and the increase in the spending power of Chinese households, Tianda Pharmaceuticals seizes the opportunity to penetrate the whole TCM industry chain from three aspects, namely Chinese medicine services, Chinese herbal medicine and TCM AI. The company has also established the "Tianda Standard", which is more stringent than the national standard to guarantee its TCM quality, and launched TDMalls, a new style Chinese medicine clinic chain. TDMall is based in the Guangdong-Hong Kong-Macao Greater Bay Area and seek to expand nationwide and even globally in the future, striving to develop into a leading brand of Chinese medicine clinic chain. The company has already launched a flagship clinic in Zhuhai, Guangdong in May 2019 and another flagship clinic in Causeway Bay, Hong Kong in February 2020. In addition, unlike the first two, the Australian TDMall is in the pipeline and will be operated as a health care center to take advantage Australia's blessed comfortable and healthy environment. In the future, the TDMall will promote womb care, pain treatment and recuperation as its signature services. Through leveraging on Internet technology, big data, artificial intelligence and other innovative technologies, the company has created "Cloud TDMall" to realize online and offline integration of Chinese medicine services and provision of remote diagnosis and treatment and consultation services, which provides the public with quality, convenient and comprehensive TCM health services, and helps the company to further promote the heritage, innovation and development of TCM.

Business performance remains solid
The company's revenue for FY2020 was HK$492 million, presenting a year-on-year decrease of 6.7% as shown in the full-year results released for the year ended 31, March 2020, However, the profit for the year attributable to shareholders was approximately HK$3.14 million, increasing 18.3% compared to the same period last year. The decline in overall revenue was mainly due to the change in national medical insurance policies, which had a significant impact on the sales volume of Cerebroprotein Hydrolysate, products produced by a subsidiary of Tianda Pharmaceuticals -Yunnan Meng Sheng Pharmaceutical Co., Ltd (Meng Sheng Pharmaceutical). However, the impact on the profit for the year attributable to shareholders was mitigated by the fact that Tianda Pharmaceuticals only held 55% in Meng Sheng Pharmaceutical. In addition, sales revenue of the Company's wholly-owned subsidiary, namely Tianda Pharmaceuticals (Zhuhai) Limited, increased by 38.3% from approximately HK$177 million in FY2019 to approximately HK$246 million in the current financial year, mainly due to its main products, namely Tuoping (Valsartan capsules) and Tuoen (Ibuprofen suspension), having great sales performance and increasing by 67.8% and 31.8% respectively as compared to that for the FYE 2019. Profit contribution from Tianda Pharmaceuticals (Zhuhai) increased by 55.4% from approximately HK$16.9 million for the FYE 2019 to approximately HK$34.2 million for the current financial year, which not only fully offset the impact of the decline in performance of Meng Sheng Pharmaceutical, but also contributed to the increase in profit for the year attributable to shareholders. Chinese herb medicines, decoction pieces and TDMall business are expected to maintain growth in the future. Tianda Pharmaceutical (Zhuhai) Limited's new research and development (R&D) and production base in Jinwan District, Zhuhai, China is expected to be ready for production in 2021 when the production capacity will be further enhanced, product variety will increase, economies of scale will maximize returns, hence proving sustained development dynamics.

Tianda Pharmaceuticals attaches importance to product R&D, and develops a wide range of products including classical TCM compound prescription, cosmetics and food products using the Cerebroprotein extraction process, and traditional Chinese medicine products such as herbal tea bag, herbal soup pack, Chinese herb syrup, health products of medicine and food with the same source, and series of mask products, etc. In response to the changes in health care reform policies, Tianda Pharmaceuticals makes every effort to consolidate and expand its generic medicine business and promote the growth of its innovative medicine business by means of diversifying sales channels, further exploring domestic and overseas markets, strengthening R&D and entering into business collaboration. At the same time, it follows national policy closely by developing TCM business with a focus on building a new clinic chain – TDMall.

Tianda Pharmaceuticals strives to build diversified channels for investors to interact with the company, thus maintaining close interaction with shareholders and investors, and promoting awareness of the capital market. The company is debt free and has been paying a steady dividend. The Board of Directors has recommended the dividend of 0.13 HK cents per share. It is believed that Tianda Pharmaceuticals will continue to drive business value to reward its shareholders in the future.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award

Adelaide, AUS, Jul 9, 2020 – (ACN Newswire) – The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. This is the first Frost & Sullivan award for the company which has seen rapid growth in the APAC region over the past year.

Avance Clinical CEO Yvonne Lungershausen

According to Frost & Sullivan:

"The Frost & Sullivan Best Practices Awards have honoured best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry to identify best practices."

Avance Clinical CEO Yvonne Lungershausen:

Commending her team of more than 100 clinical trial specialists throughout Australia and New Zealand, "We have shown, with our repeat business rate greater than 75%, that our consistent sponsor focussed culture and nimble proactive approach wins every time. This has been recognised by the research team at Frost & Sullivan and the entire Avance Clinical team are very proud.

"Australia, which has successfully managed the COVID-19 crisis, is open for business for clinical trials. This award further reinforces to the biotech community that this is an early phase specialist destination where they can turn around delayed trials. Avance Clinical are experts in facilitating fast study startup with trials typically approved and initiated in under 6 weeks."

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.

Avance specialises in supporting biotech companies with their early phase clinical trials, having conducted over 150 early phase (Phase 1 and 2) trials in the past 4 years, involving treatment of over 8,300 participants across 95 therapeutic indications.

According to Nidhi Jalali, Analyst Best Practices, Frost & Sullivan:

"Within Asia-Pacific's highly competitive CRO market, Avance Clinical stands out as a leader in early phase biotech clinical trials. Avance's reputation for high-quality clinical trial outcomes has attracted an impressive 74% repeat business rate, underscoring the company's position as a market leader.

Avance Clinical offers a highly responsive and proactive service for biotechs wanting rapid and innovative clinical trial solutions, with the highest level of data compliance. The company has grown quickly over the past year doubling staff numbers, with plans to further expand. Avance Clinical offers a real size match for biotechs, meaning better mission understandings and stronger customer service compared to the larger CROs."

In addition to the impressive COVID-19 management in Australia, a key factor in sponsor demand is the speed, access to high-quality sites and attractive cost of running trials in Australia including:
– The Australian Government financial rebate of up to 43.5% on clinical trial spend
– No IND required for clinical trials and streamlined regulatory processes
– Advanced medical, research and scientific community, leading investigators & KOLs, modern medical facilities

Australia's reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.

Learn about running your next study with Avance Clinical: https://www.avancecro.com/.

About the Frost & Sullivan Awards

The Frost & Sullivan 2020 Best Practices Awards have honoured best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry in order to identify best practices.

With a strong overall performance, Avance Clinical earns the 2020 Asia-Pacific CRO Market Leadership Award. We also recognize that your receipt of this award is the result of many individuals (employees, customers and investors) making daily choices to believe in the organization and contribute in a meaningful way to its future.

About Avance Clinical

Australia's Avance Clinical Pty Ltd has more than 20-years of experience and is now one of Australia's leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. An established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialised patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with long track records in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round taking advantage of Australia's counter-flu and allergy seasons

Media Contact:
Chris Thompson

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Emerge 2020 HR Tech Summit Concluded Successfully

Asia, Jul 9, 2020 – (ACN Newswire) – Yet again Clavent has brought HR leaders across the globe on a single platform to plant a flag on their first-ever virtual event "Emerge2020 HR Tech Summit​" organized on 25-26th June. Amidst the pandemic, Clavent is always ready to Inspire, Interact, and Innovate. Certainly establishing norms of "virtual experience" in current scenarios to assemble HR veterans to speak on divergent topics based on technological advancements to tackle challenging disruptions in the HR domain across various industries.

Meanwhile, Clavent conducted a virtual summit ensuring that they fulfill their purpose of an event to not only get insights from different sessions but also to get acquainted with fellow attendees and acquire skills from each other. Clavent brought under one platform taking charge of all the elements enabling real-time experience such as Networking Lounges, Exhibitor Booths, Polls, Discussions, Q&A to meet and greet fellow attendees.

At Emerge, Clavent predominantly touched upon three themes Innovation & Leadership, Talent Management, and Learning & Well-Being. The day started with the captive hosting that drove the whole event with enthusiasm and bridged the gap between the attendees and the speakers. He initiated the session with the exciting polls. One of the polls that you can answer right now as well "Are you in your Pajamas?" Polls ensured that the audience was heard, engaged, and were updated in real-time.

The summit began with a keynote session by Prithvi Shergill – Chief Business Officer, KPISOFT who talked about "In a crisis: CHROs Step Up to New Challenges". The session was a head turner and the speaker emphasized how to master risk and performance with four evolution stages "React, Respond, Reform & Reimagine" with three indispensable elements Workplace, Workforce, and Work. He also dug deep with the paradoxes in the coronavirus crisis and how to build trust across various projects to celebrate the milestones.

Steve Yong – CAO HR from HSBC, a proven effective change leader with the ability to create and implement various business strategies in complex global organizations emphasized on "Leverage Tech & Analytics to keep a tab on Productivity & Engagement". He spoke about how to be prescriptive in sentiment analysis and pay reviews. Everyone was enthralled about the way he brought HR and Technology in a single discussion and to fulfill personal and organizational goals.

Augustus Azariah, HR Leader from IBM and having 20+ years of experience in the industry and a key driver to bring happiness in the workforce. This was where the third session focussed on "People, Process, Automation". While Clavent again initiated the session with another poll, Augustus spoke about the purpose of being essential. He left the attendees amazed by taking them from changing the talent landscape to the journey of new normal.
The next speaker for Emerge was Komal Singh, Senior HR business partner- India & APAC at InMobi. She has been leading business priorities through people's intervention to drive focus on an enterprise model mindset. She talked about "Building a digital culture". She focused on the reality of the emerging Gig Economy & millennials workforce view. She deep dive into how an ecosystem can drive digital culture.

"Attracting GenZ" was the fourth session of Day 1 by none other than Anil Kumar Mishra, Vice president & Chief People Officer of MagicBricks. Certainly, an engaging session for all the upcoming HR leaders wherein he emphasized on how to attract Genz and how to create an exciting workplace. He also talked about how imperative it is to take care of GenZ career aspirations and how it will drive the organization to the road of success.

Dr. Ankita Singh, Senior VP & Global Head HR at CIGNEX Datamatics who has over 19 years of progressive experience in leading various aspects of HR across various domains of ITES. She talked about "Future of Work" that focused on certain topics like WFH, Gig Economy, tech-driven processes, LMS. She brought certain aspects onto the table like how to rebuild the tour business, people, and trust. How HR can be a copilot to the organization to fulfill objectives.

"Employee Experience = Customer Experience" was the topic of the next session taken by Amit Sharma CHRO from Volvo Group. He drove the session by answering if the above-mentioned terms are understood clearly by the workforce. He also bridged a gap between the two mentioned terms and how happy employees will lead to better customer experience.

Ben Eubanks, Principal Analyst Lighthouse Research & Advisory brought us an interesting topic of this age "Learning in the age of social distancing". He focused on the way to learn new skills powerfully. He also connected neuroscience, formal learning, and to explore informal learning.

Clavent was delighted to kick off day 2 with none other than Bhavya Misra, HR Director PepsiCo. She is richly experienced across a variety of roles in the HR domain in the Retail & FMCG sector. She focused on the "Role of Leadership in maintaining Work-Life Balance". In the current context and the scenario, it becomes indispensable to talk about the lines between work life and personal life. To not only introspect but retrospect what this means and how it impacts the workforce. Is it clock connectivity, expectations on responsiveness coming in the way?

"Science of well being" was the next session by Varadharaju Janardhanan, VP & Head HR [24]7.ai. He emphasized on the mental well being. To elucidate the workforce's mind space and to talk about constraints like Lockdown, Social Distancing, Working Virtually, Shortage of essentials, etc. While he talked about the above-mentioned restrictions brings the fear of the future in the employees that might result in anxiety and how it can be tackled by understanding brain science.

"Networking Break" helped to bring in an opportunity to meet and greet the fellow attendees and get to know each other and make these sessions more meaningful. Moreover, Clavent conducted "Q&A sessions" each day exclusively to bring out a childlike curiosity among every individual.

Manish Behl, Associate VP Center for the future of Work at Cognizant, spoke about "The Future of Work and AI". Manish spoke about AI can be a rocket fuel to drive organizational objectives and harness employee goals. He further talked about how AI is infusing in work culture followed by fantastic questions by curious attendees such as to drive attention from automation, employability and its effect due to COVID19.

Venkatesh Palabatla, Group CHRO Navabharat Ventures Limited shared his views on "Augmented Talent – Harnessing the cognitive capital of people at work". He brought major topics that had major implications on industries that are the Industrial revolution and COVID Crisis. He talked about building Human Capital, the need for a new organizational model that will align with the new business needs and challenges.

Susan Armstrong, Managing Partner- Global Training Transformation spoke about "Designing a Future Proof Learning Strategy". She talked about the need to engage, motivate, and develop leaders and employees. She deep-dived on the global challenges that are faced by an organization in regards to employee performance and mental health. She has also been a part of Learning and development strategies in COVID and talked about how those can be executed successfully.

Saswati Sinha, VP and Head HR-Cheil India ( Samsung Group) talked about "The Power of Collective Intelligence". She explained the real definition of CI and how technology plays a vital role in group intelligence. She also mentioned that technology is changing the way employees were working earlier and how it is bringing a change in the centralized management approach. She focused on how organizations will thrive, loose hierarchies, and embrace democracy.

Abhimanyu Choudhary Chief Business Officer at Xoxoday spoke about "Know your Employee Pulse in the age of Social Distancing". He talked about the challenges that 2020 brought. The uncertainty that calls for managing not only the work but household chores. The challenge for HR is to keep its employees motivated and engaged. He motivated the attendees to come up together and work for the upliftment of the organization overall.

The last session "The Myth of Employee Engagement" was given by Jonas Prasanna, International HR Business Partner. He brought up a few questions regarding the effectiveness of the surveys done across several organizations, and if disengagement is a bad thing? He focused on how rather than talking about an engagement that can be done to drive the culture of a workplace that brings positive results.

In the end, the day concluded with a Q&A session that brought not only questions but different perspectives of each attendee on various aspects of HR domains across industry creating a dynamic and inclusive environment. Clavent brought can't-find-anywhere-else tips from various HR Leaders across industries to be imbibed on your journey as an HR Leader.

Event Website Link – ​https://www.clavent.com/emerge-2020-hr-tech-summit/
For more information drop an email at contact@clavent.com

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Lifequest subsidiary Biopipe Global enters the United States with Shipment of its Revolutionary 100% Sludge-Free Biological Onsite Sewage Wastewater Treatment Plant to California

RIDGEFIELD PARK, NJ / CHENNAI, IN, Jul 9, 2020 – (ACN Newswire) – via NEWMEDIAWIRE — LIFEQUEST WORLD CORP (LQWC) subsidiary Biopipe Global, which has developed the world's only highly scalable onsite sludge and chemical-free sewage wastewater treatment technology, has shipped its first plant to California. With a capacity of 10m3/day (2,640 gallons/day), the plant will be installed at a campground in Southern California.

Enes Kutluca, the CEO of Biopipe, said, "Due to Covid-19, this is the first fully assembled and ready to install plant we have shipped from Turkey. We have an excellent engineering partner on the ground to install and commission the plant in the near future. We have implemented a new process with our manufacturer, PIMTAS, which will allow us to ship ready-to-install systems with capacity ranging from 2m3/day to 15m3/day. We also recognize that California Water Board (CWB) is one of the toughest water regulators in the world and we are confident that we will meet the effluent discharge standards set by CWB."

Max Khan, the President & CEO of Lifequest, said, "Given our focus on Asia and Africa, we did not intend to enter the USA market until 2021 due to all the regulatory hurdles and certifications that are required. But due to strong inquiries from various parts of the country, we decided to start with the toughest state. California faces an intractable water crisis and the recycling of wastewater is the only way out. Our BIOPIPE system is an effective solution for onsite wastewater treatment because it produces non-potable water that can be reused. The USA in general, but California in particular, represents an enormous opportunity."

About Lifequest & Biopipe

Lifequest offers both effluent treatment (ETP) and sewage treatment (STP) solutions. Biopipe, a wholly owned subsidiary, has developed a patented 100% sludge-free, chemical-free, odor-free, silent, easy to assemble and install, scalable, low cost, ecological and virtually maintenance-free onsite sewage wastewater treatment system. It treats both grey and black water. The treated water exceeds EU and all local standards for discharge and can be reused for irrigation, flushing and cleaning.

Visit: http://www.lifequestcorp.com
Contact: info@lifequestcorp.com
Telephone: +1-646-201-5242

Visit: http://www.biopipe.co
Tanmay Pawale: Tanmay@biopipe.co
Nina Aquino: Nina@biopipe.co

This press release contains forward-looking statements that reflect the Company's current beliefs, expectations or intentions regarding future events. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "will," "will be," "anticipate," "predict," "expect" "continue," "future," and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: future revenues, expenditures, capital, the adequacy of the Company's current cash and working capital to fund present and planned operations, and the growth through joint ventures. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, can be found in our current Disclosure Statements at www.otcmarkets.com. The Company anticipates that subsequent events and developments may cause views and expectations to change. The Company assumes no obligation, and specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Research on Free-state Nicotine and Coronavirus Reveals Facts More Complex than we Thought

SHENZHEN, CHINA, Jul 9, 2020 – (ACN Newswire) – On February 9, Chinese academician Zhong Nanshan published a retrospective study on novel coronavirus cases in medRxiv, a medical preprint magazine. According to Zhong's paper "Clinical characteristics of the 2019 novel coronavirus infection in China" of 1099 new coronavirus patients, 927 were never smokers (85.4%), 21 are ex-smokers (1.9%) and 137 are current smokers (12.6%). The proportion of smokers in the Chinese population is 28.1%. These data seem to indicate that smokers are far less likely to be infected with the novel coronavirus than non-smokers.(1)

On April 22, France Inter reported that a research team from the Pitie-Salpetriere Hospital in Paris, led by Jean Pierre Changeux, a member of the French Academy of Sciences, launched research asking "Can nicotine protect the human body from invasion by the novel coronavirus?" The reason is that field surveys of new patients with novel coronavirus show a puzzling fact: compared with non-smokers, smokers are less likely to be infected.

The Paris researchers surveyed 350 hospitalized patients and 130 patients with mild symptoms who did not need to be hospitalized. Based on total population data from 2018, the researchers wanted to check whether these patients smoked more than other people of the same gender and age. The conclusion is that smokers are very rare among these patients."We found that only 5% of these patients are smokers. It's a low proportion. In general, the proportion of smokers is 80% less than other coronavirus-infected patients of the same gender and age," explained Zahir Amoura, a professor of internal medicine.

On the other hand, Jean Pierre Changeux speculated that nicotine may prevent the coronavirus from attaching to objects and human surfaces. Furthermore, it may prevent the coronavirus from invading cells. This may mean nicotine can inhibit the spread of virus and the novel coronavirus pneumonia.(2,3)

According to Israel's Jerusalem Post on June 7, Israeli scientists found that smoking can provide some protection against the novel coronavirus. The results are similar to those of researchers in China, France and Italy.

Since there were conflicting reports about the impact of smoking on the risk of contracting novel coronavirus, an Israeli team led by Dr Ariel extracted data from more than 3 million adult members of Clalit, Israel's largest health service center. Novel coronavirus pneumonia seems to be reduced by half in smokers, according to the result of their research.

Of the more than 3 million adults involved in the study, 114,545 were tested for the virus, of which only 4% were positive. The researchers matched people who tested positive to those who tested negative in a ratio of 1:4, taking into account as many variables as possible, such as age, gender and race. They found that among those who tested positive, smokers accounted for 9.8% and 19% of the total population.

Smoking seems to bring some benefits, with 11.7% of those who tested positive had a history of smoking, compared with 13.9% of the general population in the study. As a result, the study showed that people with a history of smoking had a 19% lower risk of contracting the virus.(4)

The study by Professor Zahir of the Pitie Salpetriere Hospital also showed that smokers are about half as likely to be infected as other people. Of the novel coronavirus pneumonia patients who visited the hospital from February 28th to April 9th, only 4.4% of inpatients and 5.3% of outpatients smoked daily, compared with 25.4% in the general population. The study also found that smokers were 80% less likely to have severe symptoms, leading researchers to suggest that the free-state nicotine in cigarettes binds to cell receptors to block the virus.

Similarly, a study of 28 papers by University College London showed that the number of smokers infected with coronavirus was "lower than expected"; A Chinese study also found that only 6.5% of 5,300 hospitalized patients with coronavirus were smokers; A study by the Centers for Disease Control and Prevention in the United States found that only 1.3% of the more than 7000 people who tested positive were smokers, the Daily Mail of Britain reported."Our results provide compelling evidence for the current association between smoking and an individual's risk of COVID-19 infection," the researchers wrote in the paper.(6)

"The potential benefit of free-state nicotine is that it can partly explain the exacerbation or adverse consequences of smokers hospitalized for coronavirus. It is because these patients will inevitably stop taking nicotine during hospitalization," Dr. Constantinos Fasalinos from the University of Siatica, Greece, wrote in his paper for internal medicine and emergency medicine.(7)

On February 2, experts in Shenzhen, China started relevant research on the IUOC, a heat-not-burn tobacco device, which attracted their attention. The nicotine produced by one cigarette heated by IUOC is the same as that produced by a lighted one, which is free-state nicotine. But the amount of nicotine released by a heat-not-burn cigarette is twice that of a lighted one, and it is almost pure nicotine aerosol. On July 1st, researchers found that more than 600 cigarette stores in Beijing were selling the IUOC device.

Media contact:
Shenzhen Yukan Technology Co., Ltd.
Rm 1110, West Tower, Nanshan Software Park,
No.10128, Shennan Road, Nantou Street, Nanshan District, Shenzhen, China
Facebook: https://www.facebook.com/iuoctech0
E-mail: info@iuoctech.com
Website: http://www.iuoctech.com/en

(1) https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1
(2) https://www.reuters.com/article/us-health-coronavirus-france-nicotine/french-scientists-to-test-theory-that-nicotine-combats-covid-19-idUSKCN2292O8
(3) https://www.qeios.com/read/FXGQSB (A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications)
(4) https://mp.weixin.qq.com/s/33Z_KVpxzK6jMWc2Gfo2tQ
(5) https://theguardian.com/world/2020/apr/22/french-study-suggests-smokers-at-lower-risk-of-getting-coronavirus
(6) https://www.dailymail.co.uk/news/article-8264635/More-proof-smokers-risk-catching-coronavirus-expert-admits-weird.html
(7) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210099/

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Sri Trang Gloves PCL (SET: STGT) debuts on Stock Exchange of Thailand

BANGKOK, Jul 9, 2020 – (ACN Newswire) – Sri Trang Gloves (Thailand) PCL (STGT) expressed full confidence in the positive response from investors on its first trading day on the Stock Exchange of Thailand (SET), with strong business potential unaffected by the COVID-19 pandemic. It is currently the world's third largest rubber glove producer with a current production capacity of 32,619 pieces per year, and it's majority shareholder is Sri Trang Agro-Industry PCL (STA), the world's largest producer and distributor of natural latex, providing competitivel advantage on raw material. The future plan is to continuously increase production capacity to reach 100,000 pieces per year by 2032, fulfilling the growing global demand.

Ms. Jarinya Jirojkul, the Companies Chief Executive Officer, announced the debut of share trading on the SET on July 2nd with the ticker symbol STGT. The Company had completed the Initial Public Offering (IPO) of 438,780,000 shares, or 30.7 percent of all Company's issued and paid-up ordinary shares. Following the IPO with the final offering price per share of 34 baht, the Company remains confident of its potential as the world's third largest producer and distributor of rubber gloves, the high growth in performance and the overall high demand for rubber gloves both before and after the outbreak of COVID-19. All these factors would help to attract the investors' interest in STGT.

Subsequent to its listing on the SET, the Company plans to continuously expand production capacity, from 32,619 million pieces per year from 3 production facilities as of March 31st, 2020 to more than 50,000 million pieces per year by 2024 and 70,000 million pieces by 2028 to eventually reach approximately 100,000 million pieces per year by 2032, to fulfill the increasing global demand. In addition, plans are also in place to expand customer base to high-growth regions such as Asia-Pacific, Africa, South America, etc., where there is an ongoing development of the health and hygiene infrastructure and potential for high growth in demand for rubber gloves.

As for the overall picture of the 2019 performance, the Company recorded a total revenue of 12,224.02 million baht, a 10.3 percent increase over the previous year, and a net profit of 613.91 million baht, on the back of increased sales volume in new markets and the realization of exchange rate gains. Meanwhile, in Q1/2020 the Company recorded a total revenue of 3,873.28 million baht, a 28.8-percent growth over the same period of the previous year, and a net profit of 421.89 million baht, a 184.0-percent growth over the same period of the previous year.

"We intend to maintain our position as one of the 3 largest rubber glove producers and distributors in the world by increasing the production of natural rubber gloves while maintaining the proper production share of nitrile rubber gloves that use synthetic rubber as the raw material. We also utilize modern technology in our factories to improve efficiency while paying close attention to the environment and conducting our business under the concept of "Touch of Life" – because every touch is meaningful in life, with the vision to provide protection with every touch around the world," Ms Jarinya said.

Mr. Varah Sucharitakul, Executive Director of Finansa Securities, STGT's financial advisor and lead underwriter, said that STGT was the first IPO on the Stock Exchange of Thailand post-COVID-19. It is considered the largest domestic IPO deal in Thailand's capital market history. STGT's IPO has attracted the interest of both retail and institutional investors given STGT's strong business potential and status as one of the world's top rubber gloves producers. STGT's products have been exported to more than 140 countries around the word. Moreover, the outbreak of COVID-19 has led to unprecedented global awareness of health and hygiene and STGT's products can help prevent against infection through physical contact. In addition, STGT has a strong competitive advantage in raw material procurement, supported by Sri Trang Agro-Industry Public Company Limited (STA), the world's largest integrated producer and distributor of natural latex and major shareholder, and production facilities that are located in strategic rubber plantation areas.

The overall picture of the historical global demand for rubber gloves has clearly shown a continuous growth even before the outbreak of COVID-19. The Malaysian Rubber Glove Manufacturers Association (MARGMA) estimated that global demand for rubber gloves reached approximately 300,000 million pieces in 2019, representing an annual growth rate of 12.2 percent since 2016, when demand was approximately 212,000 million pieces on the back of the expansion of the medical sector and growing demand from various industries. This clearly indicates STGT's strong growth potential.

Released by MT Multimedia Co., Ltd.
for Sri Trang Gloves Plc.
Wasana "Jeab" Wongsiri
Tel: +66 84 359 0659, +66 2 612 2081 ext. 131
Email: wasana.w@mtmultimedia.com

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

AVIA ends its first online conference ‘the OTT Virtual Summit’ on a high note

SINGAPORE, Jul 9, 2020 – (ACN Newswire) – AVIA had the privilege of hosting the first major online media conference of the year, the OTT Virtual Summit, with a record turnout of over 700 delegates.

Opening the Summit this year was the Thought Leaders' panel, featuring a stellar line-up of senior executives from across the video landscape. The panel had optimism all round for the industry as a whole. "It's a great time to be a customer in this part of the world," said Tony Zameczkowski, Vice President of Business Development for Asia-Pacific at Netflix, on the growth of the region's OTT landscape.

The rise in demand for Asian content also plays a key role in this growth, with Netflix, WarnerMedia and Viu all heavily investing in local content, with Zameczkowski adding that "the streaming industry has a role to play in bringing Asian stories to the world." For WarnerMedia's Managing Director of Southeast Asia, Pacific and China, Clement Schwebig, the "most exciting part of this adventure is having what you do locally getting resonance everywhere in the world."

For VIU, the current surge in consumption has also accelerated advertising onto their platform. Helen Sou, Chief Business Officer, Asia, VIU, shared that "more and more advertisers have accelerated their spending on the digital front", hence they are seeing both subscription and advertising doing well, and are able to build "a robust and sustainable business model."

"For the consumer, the future is here… and because of the scale of the market, there is room for everyone to grow and succeed within that," added Simon Robinson, President of APAC, Discovery Asia Pacific & CFO International, Discovery International, wrapping up the first panel of the conference on a positive note.

The message of growth, opportunities and consumer engagement continued through the rest of the Summit. For those on direct-to-consumer platforms, such as Eros Now and POPS Worldwide, this has meant more collaborative partnerships, to reach audiences at a microscopic level, and to create and build a highly engaged community.

However, it was acknowledged that the industry is only in the early stage of development in monetising premium streaming video, and that is particularly true for advertising. With media buyers not spending enough time thinking about the quality of videos, premium streaming video remains under-represented and challenges still exists in measurement metrics for OTT.

As John Miskelly, APAC Investment Director, GroupM, pointed out, "It intuitively feels better to advertise inside Game of Thrones than dogs on skateboards but the question is by how much?"

However, "the consumer trend for the consumption of media is very clear, the future is going to be streamed television", added Matt Harty, SVP of Asia Pacific, The Trade Desk.

Similarly, on the advertising front, Gavin Buxton, Managing Director, Asia, SpotX shared, "Consumers are definitely coming into the ecosystem… advertisers are looking for the most effective and efficient place to be… it is a time for OTT to shine for all the benefits that it can bring."

To wrap it all up, Louis Boswell, CEO, AVIA, said, "While we regret that we were not able to host everyone in person this year, we are extremely encouraged by the turnout we had for the OTT Virtual Summit and bringing everyone together online. It is indeed a great time for the OTT industry in Asia, with more investment going into both technology as well as content in the region and there is no doubt that we are going to see growth in streaming video in the years ahead."

The OTT Virtual Summit is generously supported by Gold Sponsor Brightcove; Official Pit-Stop Sponsor TV5MONDE and Silver Sponsors Broadcast Professional, Conviva, Limelight, MediaKind, Netflix, PubMatic and Vuulr.

About the Asia Video Industry Association

The Asia Video Industry Association (AVIA) is the trade association for the video industry and ecosystem in Asia Pacific. It serves to make the video industry stronger and healthier through promoting the common interests of its members. AVIA is the interlocutor for the industry with governments across the region, leads the fight against video piracy and provides insight into the video industry through reports and conferences aimed to support a vibrant video industry.

For media enquiries and additional background please contact:
Charmaine Kwan
Head of Marketing and Communications
Email: charmaine@avia.org
Website: www.avia.org
LinkedIn: www.linkedin.com/company/asiavideoia
Twitter: @AsiaVideoIA

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Los Angeles Digital Marketing Agency Scores U.S. National Success

LOS ANGELES, CA., Jul 8, 2020 – (ACN Newswire) – Emergent marketing agency NITRO PLUG Digital Marketing was ranked among the best digital marketing agencies in the US, winning a 2020 National Excellence Award in Digital Marketing. Attracting national attention, NITRO PLUG was further recognized by multiple agencies and companies as being one of the top digital marketing agencies in L.A. today.

From Hollywood to Beverly Hills, the city of L.A. is filled with many longstanding and impressive digital marketing firms. Among these titans is a relatively new and up and coming firm, NITRO PLUG Digital Marketing. NITRO PLUG is making waves in marketing and professional communities across the country as it is formally recognized for its achievements in boosting business for clients across the board. Established in 2017 NITRO PLUG has already proven successful in acquiring a large repertoire of clients, ranging from large construction companies to corporate law firms. NITRO PLUG has been successful in managing their digital marketing needs, resulting in increased traffic and sales for their clients.

As an agency, NITRO PLUG has been recognized for their experiences and triumphs in SEO, PPC, Social Media, and Email Marketing. As a result of their award-winning marketing strategies, NITRO PLUG has helped hundreds of clients achieve high rankings on Google, as well as generate targeted leads with large scale paid advertising. Further acclaim, as reflected by expertise.com and nogood.io has noted the digital agency for their skilled optimization of client websites and conversion. Every member of NITRO PLUG has more than seven years of experience in the digital marketing industry, ensuring every client is assigned a team of capable professionals. As reflected by being #7 on the nogood.io ranking of top digital marketing agencies in L.A., many account NITRO PLUG's successes to their active and experienced team of digital marketing experts.

"It's really exciting for our team and clients," reflects Elizeth Shah, NITRO PLUG's CEO. "I am truly honored to be recognized for the work we're doing here and I'm so proud of the team, it's been very rewarding seeing everyone come together to help us get to where we are today. Winning the 2020 National Excellence Award in Digital Marketing was an amazing first step. I think I speak for all of us when I say it felt great. We're really coming into our own as a full-service digital marketing agency."

NITRO PLUG is exactly that. A full-service agency is growing bigger every day. As an UpCity certified partner and one of a hundred 2020 National Excellence Award recipients, clients know what to expect when looking to NITRO PLUG for high-level digital marketing. Many anticipate further growth as NITRO PLUG continues to be recognized for its excellent standard and quality of work.

The key to their success is their marketing strategy. NITRO PLUG has taken a very personalized approached to building marketing plans and executing them flawlessly. Before beginning and marketing project, the agency first strives to understand exactly what the client needs, and every plan is then tailored specifically for each unique business. NITRO PLUG's CEO, Elizeth Shah noted, "it's simple, we provide solutions to our client's problems." This unique and prescriptive approach makes the working relationship between NITRO PLUG and their clients extremely special, and therefore commences with a complimentary online marketing analysis of each client in comparison with their competitor's online performance. This winning strategy has been recognized by dozens of clients in NITRO PLUG's excellent online ratings and client testimonials.

"…they continued to impress us with strong results week after week." – Cal First Contracting

"Everything from the introduction call, to the intake, and the campaign management has been absolutely phenomena!" – JJ Law

"We spoke to several internet marketing providers but it didn't seem as though any of them had the level of experience that Nitro Plug Digital Marketing had, and we were right. They've taken our business to new heights" – Warner Law

NITRO PLUG Digital Marketing is a full-service digital marketing agency. They have extensive experience in Search Engine Optimization (SEO), Pay-Per-Click (PPC) Advertising, Social Media Management, and Email Marketing. Recently named one of the Top Digital Marketing Agencies in the United States; they've helped hundreds of clients rank higher on Google; generate more targeted leads with paid advertising; convert more email subscribers, and optimize their website for conversion.

Media contact:
NITRO PLUG Digital Marketing
Tel: +1 (888) 983 1230
Email: contact@nitroplug.com
Website: https://www.nitroplug.com/
Facebook: https://www.facebook.com/nitroplug
Upcity: https://upcity.com/profiles/nitro-plug/
Instagram: https://www.instagram.com/nitro.plug

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com